BIOCODEX – SUBSTIPHARM agreement for the sale of Hydrocortisone.

Hydrocortisone is indicated for acute adrenal insufficiency

Press release

SUBSTIPHARM has recently acquired the rights of HYDROCORTISONE 100 mg injectable from BIOCODEX, including marketing authorizations.

HYDROCORTISONE 100 mg injectable is available in packs of:

  • 1 vial + 1 ampoule of solvent
  • 100 vials + 100 ampoules of solvent
  • 100 vials

Hydrocortisone is indicated for acute adrenal insufficiency and is currently marketed in Morocco, Israel, France, Iraq and Lebanon.

BIOCODEX remains SUBSTIPHARM’ s distributor in Morocco for the product.

Leopold Berthier, Substipharm Chief Executive Officer, commented:

“This acquisition provides greater scale and diversity across our growing Business to Consumer portfolio, while bringing additional direct presence in our export markets. With Hydrocortisone, SUBSTIPHARM is taking another step forward to support its rapid growth pattern outside Europe”.

Nicolas Coudurier, Biocodex Chief Executive Officer, commented:

Pleased to reinforce our partnership with Substipharm, Biocodex is focusing its international development on strategic priorities: Microbiota, Women’s Health, Orphan Diseases”